Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...

Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...

A Phase 3 trial investigating Boehringer Ingelheim’s nerandomilast in idiopathic pulmonary fibrosis hit its primary endpoint, ...

The Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.

Phase Ib met its primary endpoint, demonstrating a meaningful objective response rate (ORR) of 66.7%, as assessed by blinded ...

Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results GlobeNewswire September 05, 2024 Ingelheim, Germany and Basel, ...

Phase Ib met its primary endpoint, demonstrating a meaningful objective response rate (ORR) of 66.7%, as assessed by blinded independent central review (BICR)1Preliminary activity in patients with bra ...

John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses exciting developments in HER2-targeted ...

Terns Pharmaceuticals shares surged 34% on positive results for obesity treatment drug TERN-601 in early-stage trial, ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Nihar R. Desai, MD ...

Our study shows the feasibility of real-time estimation of antibody kinetics before SARS-CoV-2 variant emergence. This estimation is valuable for understanding how specific combinations of SARS-CoV-2 ...